BRAF and lung adenocarcinoma: The aim of our study was to analyze the mutational rate of EGFR, KRAS, BRAF, ERBB2 and PI3KCA in a large cohort of 2,219 unselected French patients presenting in routine clinical practice for first line treatment decision of metastatic or recurrent lung adenocarcinoma.